FINNENCE ▪ THE WIRE FILE

THE WIRE · № 67982

News■ Unclear/unknown

SheMed Launches At-Home PMOS Screening Kit, Connecting Women to Answers and Care

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-06 15:57 UTC

KINDNews

DIRECTION■ Unclear/unknown

SOURCES1

ENTITIES1

STORY SIZESTANDALONE

FIRST SEEN2026-10-06 15:57 UTC

LAST UPDATE2026-10-06 15:57 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A new at-home screening kit targets women's metabolic care, a niche diagnostics launch.

Small healthcare product launch

CATALYST TO WATCH

Adoption or reimbursement

MAIN RISK

Low adoption, no scale

FULL DISPATCH

New screening service combines testing for up to 19 health markers, clinician review and personalised next steps in one platform LONDON, Oct. 6, 2026 /PRNewswire/ -- SheMed, a UK women's health company providing personalised metabolic care through at-home blood testing, clinician-led...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01prnewswireprnewswire.com · PRIMARY2026-10-06 15:57 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→CORRELATIONshares Healthcare
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation2026-10-06 20:15 UTC

→CORRELATIONshares Healthcare
Encompass Health Rehabilitation Hospital of Bangor now open in Maine2026-10-06 20:30 UTC

→CORRELATIONshares Healthcare
Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway2026-10-06 20:30 UTC

←CORRELATIONshares Healthcare
Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms2026-10-06 08:21 UTC

←CORRELATIONshares Healthcare
New Phase 3 trial: J-LINX: Japan LINerixibat eXtension Study — GlaxoSmithKline2026-10-06 12:00 UTC

←CORRELATIONshares Healthcare
New Phase 3 trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity — Novo Nordisk A/S2026-10-06 12:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.